Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal CancerTodd M. Pitts, Stephen Leong|PLoS ONE|2014Cited by 52
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancerS. Lindsey Davis, Todd M. Pitts|BMC Cancer|2022Cited by 27
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosisStephen G. Smoots, Todd M. Pitts|Breast Cancer Research|2024Cited by 26